Editor-in-Chief |
|
|
Ronald W. Ellis Senior Vice President & Chief Technology Officer NasVax Ltd; Ness Ziona, Israel |
|
Associate Editors |
|
|
Sujit K. Bhattacharya |
National Institute of Cholera and Enteric Diseases; Kolkata, India |
|
Sally Blower |
David Geffen School of Medicine, UCLA; Los Angeles, California USA |
|
Joel Bozue |
United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Maryland USA |
|
Robert S. Daum |
University of Chicago; Chicago, Illinois USA |
|
Heather Davis |
Coley Pharmaceutical Group; Kanata, Ontario Canada |
|
John Donnelly |
Novartis Vaccines and Diagnostics; Siena, Italy |
|
Robert Edelman |
University of Maryland School of Medicine; Baltimore, Maryland USA |
|
John Edmunds |
Communicable Disease Surveillance Centre; London, UK |
Jean-Louis Excler |
International AIDS Vaccine Initiative; Trelex, Switzerland |
|
Ian Feavers |
National Institute for Biological Standards and Control; Potters Bar, UK |
Ricardo Galler |
Instituto de Tecnologia em Imunobiologicos, BioManguinhos; Rio de Janeiro, Brasil |
|
Nathalie Garcon |
GlaxoSmithKline Biologicals; Rixensart, Belgium |
|
Gregory M. Glenn |
Intercell USA Inc.; Gaithersburg, Maryland USA |
|
Michael F. Good |
Queensland Institute of Medical Research; Queensland, Australia |
|
Carlos Guzman |
Helmholtz Centre for Infection Research; Braunschweig, Germany |
|
Michael G. Hanna, Jr. |
Intracel; Frederick, Maryland USA |
|
Leonard C. Harrison |
Walter and Eliza Hall Institute of Medical Research; Parkville, Victoria, Australia |
Luc Hessel |
Sanofi Pasteur MSD; Lyon, France |
|
Genevieve Inchauspe |
Transgene; Lyon, France |
|
Mark Kane |
Consultant |
|
Helena Kayhty |
National Public Health Institute; Helsinki, Finland |
|
Kevin Killeen |
Matrivax Corporation; Boston, Massachusetts USA |
|
Keith P. Klugman |
Emory University; Atlanta, Georgia USA |
|
Wayne C. Koff |
International AIDS Vaccine Institute; New York, New YorkUSA |
|
Reiner Laus |
BN ImmunoTherapeutics; Mountain View, California USA |
|
Orin S. Levine |
Johns Hopkins School of Public Health; Baltimore, Maryland USA |
|
Philip O. Livington |
Memorial Sloan-Kettering Cancer Center; New York, New YorkUSA |
|
Nils Lycke |
Univeristy of Göteborg; Göteborg, Sweden |
|
C. Russ Middaugh |
University of Kansas; Lawrence, Kansas USA |
|
Timothy F. Murphy |
University at Buffalo, SUNY; Buffalo, New York USA |
|
Mark J. Newman |
GeoVax, Inc.; Smyrna, Georgia USA |
Miguel O'Ryan |
University of Chile; Santiago, Chile |
|
Lawrence Paoletti |
Harvard Medical School; Boston, Massachusetts USA |
|
Michael Pichichero |
University of Rochester Medical Center; Rochester, New York USA |
|
Gerald B. Pier |
Harvard Medical School; Boston, Massachusetts USA |
|
Michael W. Russell |
University at Buffalo, SUNY; Buffalo, New York USA |
|
Jo Southern |
Institute of Child Health; London, UK |
|
Pramod K. Srivastava |
Center for Immunotherapy, University of Connecticut; Farmington, Connecticut USA |
|
James Tartaglia |
Sanofi Pasteur; Toronto, ON, Canada |
|
Jeffrey Ulmer |
Novartis Vaccines; Cambridge, MA USA |
|
Matthias von Herrath |
La Jolla Institute for Allergy and Immunology; San Diego, California USA |
|
Brian J. Ward |
McGill University; Montreal, QC Canada |
|
Michael Watson |
Sanofi-Pasteur; Lyons, France |
|
David B. Weiner |
University of Pennsylvania; Philadelphia, Pennsylvania USA |
|
Bruce G. Weniger |
Centers for Disease Control and Prevention; Atlanta, Georgia USA |
Editorial Board |
|
|
Sudhir Agrawal |
Idera Pharmaceuticals, Inc.; Cambridge, Massachusetts USA |
|
Francis Andre |
Atobis S.A.; Brussels, Belgium |
|
Ruth Arnon |
Weizmann Institute of Science; Rehovot, Israel |
|
Stephen Black |
Kaiser-Permanente; Oakland, California USA |
|
Steven N. Chatfield |
Health Protection Agency; London, UK |
|
Robert Chen |
Centers for Disease Control and Prevention; Atlanta, Georgia USA |
|
Ron Dagan |
Ben-Gurion University; Beer-Sheva, Israel |
|
Angus G. Dalgleish |
St. George's Hospital Medical School; London, UK |
Anne De Groot |
EpiVax, Inc.; Providence Rhode Island USA |
|
R. Gordon Douglas |
Consultant; Niantic, Connecticut USA |
|
Kathryn Edwards |
Vanderbilt University; Nashville, Tennessee USA |
|
José Esparza |
Bill & Melinda Gates Foundation; Seattle, Washington USA |
|
Ian Frazer |
University of Queensland; Queensland, Australia |
|
Lance K. Gordon |
ImmunoBiologics Corp. |
|
Jaap Goudsmit |
Crucell; Amsterdam, The Netherlands |
|
Dan Granoff |
Oakland Research Institute; Oakland, California USA |
|
Brian Greenwood |
London School of Hygiene and Tropical Medicine; London, UK |
|
Marion F. Gruber |
Food and Drug Administration; Rockville, Maryland USA |
|
Ian Gust |
University of Melbourne; Parkville, Victoria, Australia |
|
Scott A. Halperin |
Dalhousie University; Halifax, NS, Canada |
|
Karl Erik Hellstrom |
Harborview Medical Center; Seattle, Washington USA |
David Kaslow |
Merck Research Laboratories, West Point, Pennsylvania USA |
|
Myron M. Levine |
University of Maryland School of Medicine; Baltimore, Maryland USA |
|
Alf Lindberg |
Nobel Foundation; Stockholm, Sweden |
|
Philip Minor |
National Institute of Biological Standards and Control; Hertfordshire, UK |
|
Thomas Monath |
Kleiner Perkins Caufield & Byers; Harvard, Maryland USA |
|
Paul A. Offit |
The Children's Hospital of Philadelphia; Philadelphia, Pennsylvania USA |
|
Stanley A. Plotkin |
Sanofi Pasteur; Doylestown, Pennsylvania USA |
|
Regina Rabinovich |
Bill & Melinda Gates Foundation; Seattle, Washington USA |
|
Philip K. Russell |
Albert B. Sabin Vaccine Institute; Potomac, Maryland USA |
|
David Salisbury |
UK Department of Health; London, UK |
|
Bing Sun |
Chinese Academy of Sciences; Shanghai, China |
|
John Treanor |
University of Rochester; Rochester, New York, USA |
|
Howard L. Weiner |
Harvard Medical School; Boston, Massachusetts USA |
Advertisements
